Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Fate of Avastin in early-stage cancer uncertain after second Phase III failure in colon cancer

This article was originally published in Scrip

Executive Summary

Roche is facing further disappointment with its top selling drug, Avastin (bevacizumab) – which is so far approved for advanced/metastatic cancer in a number of tumour types – after the anti-angiogenic agent failed in its second Phase III trial in early-stage colon cancer to reduce the risk of disease recurrence. Meanwhile, the FDA has delayed its much-anticipated decision on Avastin's use in metastatic breast cancer after the company submitted new information.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts